Nansu Tech Secures Tens of Millions in Pre-B Funding to Advance Closed-Loop Brain-Computer Interface Digital Therapeutics
Nans Tech
Developer of Digital Therapeutics for Generalized Brain Dysfunction
On June 23, 2026, Hangzhou Nansu Technology Co., Ltd. (hereinafter referred to as “Nans Tech”) announced the completion of its Pre-B financing round, raising tens of millions of yuan. The round was led by Plum Ventures, with Jiangxi Financial Holdings Group participating as a co-investor.
The financing funds will be primarily used for the following purposes:
"Time-Targeted" Closed-Loop Brain-Computer Interface Technology Platform Development;
Clinical validation, regulatory submission, and commercialization of combination therapy products integrating Digital Therapeutics (DTx) with electrical modulation;
Perfection of the industrial ecosystem and service network.
Date of Establishment: January 16, 2019
Headquarters Location: Hangzhou, Zhejiang Province
Corporate Positioning: Focused on the research and development of digital medical products and services for pan-cerebral functional disorders, including speech-language, hearing, and cognitive impairments
Key Business Areas: Digital therapeutics for brain dysfunction and neuromodulation technologies, with products designed for the rehabilitative treatment of patients with language disorders, cognitive impairments, autism spectrum disorder, attention-deficit/hyperactivity disorder, and learning difficulties.
The company’s legal representative is Wang Ningyuan. It has established R&D centers and production bases in Shenzhen and Anji, Huzhou, respectively. The company has independently built the Brainheal Internet Hospital, an online platform connecting in-hospital services with out-of-hospital home-based rehabilitation.
Core Product Types:
"Xiaonan Ting Shuo" Speech and Language Assessment and Training System
For speech and language training in patients with speech-language disorders and cognitive impairments
Supports institutional training and remote homeHome Training Scenario
Includes functional modules such as intelligent assessment, automated IEP generation, specialized oral-motor strengthening, visual feedback training, and intelligent speech evaluation.
"Xiaonan Zhixing" Digital Therapeutic Product for Autism Spectrum Disorder
Digital Rehabilitation Training for Patients with Cognitive Impairment and Autism
Digital-Electrical Combination Therapy System (Under Development)
First Product Focuses on Language Barriers
Integrating Digital Therapeutics Task Stimulation with Electrical Modulation Techniques
The company stated that it has established a technical pathway of "neural sensing—target identification—adaptive regulation—data feedback."
Applicable Departments or Scenarios:
Department of Rehabilitation, Department of Pediatrics, and Rehabilitation Center
Out-of-Hospital Home Rehabilitation Scenarios
Technical Direction:
Digital Therapeutics Software
Non-Invasive Brain-Computer Interface Technology ("Temporal Target" Neural Encoding Strategy)
Neural Electrical Stimulation Modulation Technology
According to NeuroFuture’s search of the National Medical Products Administration (NMPA) website, the company’s approved medical device registration certificates are listed in the table below:
According to NeuroFuture's inquiry on the Qichacha website, the company's financing history is as follows:
According to NeuroFuture’s query on the Qichacha website, the company’s patents are listed in the table below:
If there are any inaccuracies or infringement issues in the above information, please feel free to contact the author for removal. Thank you!
